Radimmune Therapeutics
David is a co-founder of Radimmune, a recognized expert in clinical radiation oncology, and a driving force behind the development of radioimmunotherapy targeting centrin-1. He is a clinical instructor at the David Geffin School of Medicine at UCLA, where he also completed his own medical and specialty training.
This person is not in the org chart
This person is not in any offices
Radimmune Therapeutics
Radimmune Therapeutics is an early-stage biotechnology company that pioneers innovative therapies. It develops antibody-targeted radiation therapeutics, also known as radioimmunotherapy and liquid radiation. An alpha-emitting and/or beta-emitting radioisotope is guided to a universal target antigen. Radimmune has developed proprietary antibodies targeting extracellular accumulations of, normally, intracellular substances.